We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Axovant Gene Therapies Ltd | NASDAQ:AXGT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.10 | 2.09 | 2.11 | 0 | 01:00:00 |
Delaware | 001-37418 | 85-3863315 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1501 Broadway 12th Floor New York, New York 10036 (Address of principal executive offices) (Zip Code) |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||||
☒ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Common Stock, par value $0.00001 per share | SIOX | The Nasdaq Stock Market LLC |
SIO GENE THERAPIES INC. | |||||||||||||||||
Dated: | December 14, 2022 | ||||||||||||||||
By: | /s/ David Nassif | ||||||||||||||||
Name: | David Nassif | ||||||||||||||||
Title: | Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel |
1 Year Axovant Gene Therapies Chart |
1 Month Axovant Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions